We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-4.61%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.5B
AUM Growth
-$546M
Cap. Flow
-$309M
Cap. Flow %
-6.85%
Top 10 Hldgs %
82.03%
Holding
109
New
17
Increased
29
Reduced
12
Closed
18

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$24.5M
2
ATH
Athene Holding Ltd. Class A Common Shares
ATH
+$18.5M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$18.4M
4
ZTO icon
ZTO Express
ZTO
+$14.4M
5
CELG
Celgene Corp
CELG
+$11.1M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$32.3M
2
BAC icon
Bank of America
BAC
+$19.3M
3
ARRY
Array Biopharma Inc
ARRY
+$16.6M
4
MS icon
Morgan Stanley
MS
+$13.2M
5
APTV icon
Aptiv
APTV
+$10.7M

Sector Composition

Rank Sector Weight
1 Consumer Staples 46.77%
2 Healthcare 25.98%
3 Consumer Discretionary 7.97%
4 Financials 0.43%
5 Industrials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
26
CALL
Sarepta Therapeutics
SRPT
$1.65B
$16.5M 0.37%
600,000
+500,000
+500% +$20.1M
PFE icon
27
CALL
Pfizer
PFE
$143B
$16.2M 0.36%
527,000
– –
VRTX icon
28
CALL
Vertex Pharmaceuticals
VRTX
$124B
$14.7M 0.33%
+200,000
New +$16.3M
LLY icon
29
CALL
Eli Lilly
LLY
$1.09T
$14.7M 0.33%
+200,000
New +$14.9M
BMRN icon
30
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
$12.4M 0.28%
+150,000
New +$12.9M
NKTR icon
31
Nektar Therapeutics
NKTR
$2.3B
$12.3M 0.27%
66,667
– –
ZTO icon
32
ZTO Express
ZTO
$18.3B
$12.1M 0.27%
+1,000,000
New +$14.4M
CELG
33
DELISTED
Celgene Corp
CELG
$11.6M 0.26%
+100,000
New +$11.1M
KITE
34
DELISTED
Kite Pharma, Inc.
KITE
$11.2M 0.25%
250,000
-65,000
-21% -$3.19M
ARRY
35
DELISTED
Array Biopharma Inc
ARRY
$11M 0.24%
1,250,000
-2,250,000
-64% -$16.6M
INCY icon
36
CALL
Incyte
INCY
$25.3B
$10M 0.22%
100,000
– –
IONS icon
37
CALL
Ionis Pharmaceuticals
IONS
$9.03B
$9.57M 0.21%
200,000
– –
ONC
38
BeOne Medicines Ltd
ONC
$33.9B
$9.11M 0.2%
+300,000
New +$9.43M
FOLD
39
DELISTED
Amicus Therapeutics
FOLD
$8.7M 0.19%
1,750,000
-150,000
-8% -$1.04M
AGEN
40
Agenus
AGEN
$280M
$8.24M 0.18%
101,900
+50,950
+100% +$5M
HZNP
41
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$8.09M 0.18%
500,000
+150,000
+43% +$2.72M
IRWD icon
42
Ironwood Pharmaceuticals
IRWD
$596M
$7.9M 0.18%
617,154
+358,200
+138% +$4.52M
SAGE
43
DELISTED
Sage Therapeutics
SAGE
$7.66M 0.17%
150,000
-50,000
-25% -$2.36M
ALNY icon
44
CALL
Alnylam Pharmaceuticals
ALNY
$38.2B
$7.49M 0.17%
200,000
+100,000
+100% +$4.19M
AVXS
45
DELISTED
AveXis, Inc. Common Stock
AVXS
$7.16M 0.16%
150,000
-50,000
-25% -$2.67M
ATRA icon
46
Atara Biotherapeutics
ATRA
$70.5M
$7.1M 0.16%
20,000
+11,000
+122% +$4.66M
MCRB icon
47
Seres Therapeutics
MCRB
$46.3M
$6.93M 0.15%
35,000
+10,000
+40% +$2.18M
JD icon
48
CALL
JD.com
JD
$43.4B
$6.36M 0.14%
250,000
– –
MS icon
49
CALL
Morgan Stanley
MS
$324B
$6.34M 0.14%
+150,000
New +$5.67M
BLUE
50
CALL
DELISTED
bluebird bio
BLUE
$6.17M 0.14%
7,720
+3,860
+100% +$3.07M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2016 Portfolio in Review

As of Q4 2016, Artal Group held 109 positions worth $4.5B, down 11% from $5.05B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Artal Group withdrew a net $309M in Q4 2016, closing 18 positions and reducing 12 holdings. Its most notable exit was Goldman Sachs, an estimated $32.3M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 47% of assets, up from 41% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Alexion Pharmaceuticals worth $24.5M.

  • Artal Group's largest Q4 2016 buy was Alexion Pharmaceuticals: 200,000 shares worth $24.5M.
  • Artal Group added most to Agios Pharmaceuticals in Q4 2016, an estimated $18.4M increase.
  • Artal Group's biggest Q4 2016 reduction was Array Biopharma Inc, cutting an estimated $16.6M.
  • Artal Group fully exited Goldman Sachs in Q4 2016, selling an estimated $32.3M.
  • Artal Group's ten largest holdings make up 82% of its $4.5B portfolio in Q4 2016.
  • Artal Group opened 17 new positions and closed 18 in Q4 2016.
  • Artal Group's portfolio value fell 11% quarter-over-quarter to $4.5B.

Based on Artal Group's 13F filing for Q4 2016, filed 14 Feb 2017.